Learn Why Op Financial Ltd Purchased Novabay Pharmaceuticals, Inc Stake?

May 17, 2018 - By Ash Ash

NovaBay Pharmaceuticals, Inc. (NYSEAMERICAN:NBY) Logo

The New Op Financial Ltd Holding in Novabay Pharmaceuticals, Inc

Op Financial Ltd reported SC 13D form with the SEC for Novabay Pharmaceuticals, Inc. Access it here: 000143774918010263. As reported by Op Financial Ltd, the filler owns 9.9% or 1,700,000 shares of the Health Care–company.

Novabay Pharmaceuticals, Inc stake is new for [reportingPerson]. Date of activity: February 8, 2018. This shows Op Financial Ltd’s positive view for Novabay Pharmaceuticals, Inc.

Reasons Why Op Financial Ltd Bought – Novabay Pharmaceuticals, Inc Stock

Item 4. Purpose of Transaction

All Shares were acquired based upon the Reporting Person’s belief that these securities represented an attractive investment opportunity.

(d) On March 21, 2018, the Board of Directors of the Company elected Yanbin (Lawrence) Liu as a director of the Company. Mr. Liu is the Joint Chief Operating Officer & Head of Direct Investment of OP Financial. The Reporting Person sought the appointment of Mr. Liu to the Board of Directors of the Company to provide greater oversight over its investment in the Company common stock and to strengthen its partnership with the Company in the Asia-Pacific region.

SEC Form 13D.

Analysts await NovaBay Pharmaceuticals, Inc. (NYSEAMERICAN:NBY) to report earnings on August, 9. They expect $-0.05 earnings per share, up 54.55 % or $0.06 from last year’s $-0.11 per share. After $-0.14 actual earnings per share reported by NovaBay Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts -64.29 % EPS growth.

The stock decreased 3.39% or $0.1 during the last trading session, reaching $2.85. About 6,805 shares traded or 16.32% up from the average. NovaBay Pharmaceuticals, Inc. (NYSEAMERICAN:NBY) has declined 12.00% since May 18, 2017 and is downtrending. It has underperformed by 23.55% the S&P500.

NovaBay Pharmaceuticals, Inc., a biopharmaceutical company, develops, makes, and markets non-antibiotic and anti-infective products for the eye care market in the United States, China, and internationally. The company has market cap of $48.71 million. It offers Avenova, a prescription product for cleansing and removing foreign materials, including microorganisms and debris from skin around the eye; NeutroPhase for wound care market; CelleRx for the aesthetic dermatology market; Aganocide compounds patented synthetic molecules for use against bacteria, viruses, and fungi; auriclosene irrigation solution for urology; and intelli-Case, a device for soft and rigid gas permeable contact lenses. It currently has negative earnings. NovaBay Pharmaceuticals, Inc. has collaboration and license agreement with Virbac to develop auriclosene, a proprietary compound for veterinary markets.

NovaBay Pharmaceuticals, Inc. (NYSEAMERICAN:NBY) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: